Core Viewpoint - Liminatus Pharma, Inc. is exploring the inclusion of regulated digital asset strategies in its treasury management to enhance capital efficiency while maintaining its focus on developing cancer immunotherapies [1][2][3] Group 1: Company Overview - Liminatus Pharma, Inc. is a preclinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies [4] - The company is advancing a pipeline of novel therapies that target cancer antigens and tumor-specific immune responses [4] Group 2: Strategic Review - The internal review aims to assess innovative financial instruments, including blockchain-based assets, to enhance treasury efficiency and diversify non-operating capital reserves [2][3] - The review is part of the company's commitment to strong financial stewardship and balance sheet optimization [2] Group 3: Management's Commitment - The CEO of Liminatus emphasizes that the company remains committed to developing life-changing cancer therapies while responsibly managing its treasury [3] - The exploration of digital assets is described as an exploratory process, with no current agreements in place regarding their acquisition or use [3]